Pu-H71

Pu-H71

SCHEMBL15980469

CC(C)NCCCn1c(Sc2cc3c(cc2[131I])OCO3)nc2c(N)ncnc21

nearest known ligand 0.81

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 15/20 0.81
HSP90AB1 P08238 11/20 0.81
HSP90B1 P14625 5/20 0.81
TRAP1 Q12931 5/20 0.81
ERBB2 P04626 4/20 0.81
HDAC3 O15379 1/20 0.55
HDAC4 P56524 1/20 0.55
HDAC1 Q13547 1/20 0.55
HDAC7 Q8WUI4 1/20 0.55
HDAC2 Q92769 1/20 0.55
HDAC10 Q969S8 1/20 0.55
HDAC11 Q96DB2 1/20 0.55
HDAC8 Q9BY41 1/20 0.55
HDAC6 Q9UBN7 1/20 0.55
HDAC9 Q9UKV0 1/20 0.55
HDAC5 Q9UQL6 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15980494 0.96 HSP90AA1 (0.74) HSP90AA1HSP90AB1HSP90B1TRAP1ERBB2
SCHEMBL11980434 0.90 HSP90AA1 (0.82) HSP90AA1HSP90AB1HSP90B1TRAP1ERBB2
Pu-H71 SCHEMBL1857579 0.90 HSP90AA1 (1.00) HSP90AA1HSP90AB1HSP90B1TRAP1ERBB2
SCHEMBL21792262 0.90 HSP90AA1 (0.84) HSP90AA1HSP90AB1HSP90B1TRAP1ERBB2
Pu-H71 SCHEMBL29521485 0.90 HSP90AA1 (0.81) HSP90AA1HSP90AB1HSP90B1TRAP1ERBB2
SCHEMBL1864188 0.90 HSP90AA1 (1.00) HSP90AA1HSP90AB1HSP90B1TRAP1ERBB2
Pu-H71 SCHEMBL15980498 0.90 HSP90AA1 (0.81) HSP90AA1HSP90AB1HSP90B1TRAP1ERBB2
Pu-H71 SCHEMBL29414148 0.90 HSP90AA1 (1.00) HSP90AA1HSP90AB1HSP90B1TRAP1ERBB2
SCHEMBL15980503 0.88 HSP90AA1 (0.67) HSP90AA1HSP90AB1HSP90B1TRAP1ERBB2
SCHEMBL17449240 0.88 HSP90AA1 (0.64) HSP90AA1HSP90AB1HSP90B1TRAP1ERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9994573-B2 Methods and reagents for radiolabeling MEMORIAL SLOAN-KETTERING CANCER CENTER (US) 2018-06-12 US disclosed
US-20170304470-A1 HSP90-TARGETED INFLAMMATION AND INFECTION IMAGING AND THERAPY MEMORIAL SLOAN KETTERING CANCER CENTER (US) 2017-10-26 US disclosed
US-20170029426-A1 METHODS AND REAGENTS FOR RADIOLABELING MEMORIAL SLOAN-KETTERING CANCER CENTER (US) 2017-02-02 US disclosed
US-9555137-B2 Uses of labeled HSP90 inhibitors SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2017-01-31 US disclosed
US-20160015837-A1 HSP90-TARGETED CARDIAC IMAGING AND THERAPY MEMORIAL SLOAN-KETTERING CANCER CENTER 2016-01-21 US disclosed
US-20140294725-A1 USES OF LABELED HSP90 INHIBITORS SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2014-10-02 US disclosed
US-20140242602-A1 USES OF LABELED HSP90 INHIBITORS CORNELL UNIVERSITY (US) 2014-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170304470-A1 HSP90-TARGETED INFLAMMATION AND INFECTION IMAGING AND THERAPY HSP90AB1, HSP90AA1, HSP90B1 HSP90AA1 2/4885HSP90AB1 1/4885HSP90B1 3/4885
US-20160015837-A1 HSP90-TARGETED CARDIAC IMAGING AND THERAPY HSP90AB1, HSP90AA1, HSP90B1 HSP90AA1 2/4885HSP90AB1 1/4885HSP90B1 3/4885
US-20170029426-A1 METHODS AND REAGENTS FOR RADIOLABELING HSP90AB1, HSP90B1, HSP90AA1 HSP90AA1 3/4885HSP90AB1 1/4885HSP90B1 2/4885
US-20140294725-A1 USES OF LABELED HSP90 INHIBITORS HSP90AB1, HSP90B1, HSP90AA1 HSP90AA1 3/4885HSP90AB1 1/4885HSP90B1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.